Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens
Copyright © 2022 Elsevier Ltd. All rights reserved..
OBJECTIVES: The interaction between tumor cells and stroma is critical in tumorigenesis, tumor neo-angiogenesis and cancer progression. The aims of this study were to: (i) evaluate the concordance between tumor-stroma ratio (TSR) and microvascular density (MVD) on paired biopsy and surgical specimens of laryngeal carcinoma (LSCC); (ii) investigate the association of TSR with angiogenesis (CD105- and CD31-assessed MVD); (iii) assess the prognostic role of TSR and MVD evaluated on preoperative biopsies and paired surgical specimens.
METHODS: TSR, CD105- and CD31-assessed MVD were analyzed in paired biopsies and surgical specimens of 43 consecutive cases.
RESULTS: TSR showed good agreement between biopsies and surgical specimens (AC1 statistic: 0.7957). In biopsies, TSR low/stroma-rich cases showed higher CD105-assessed MVD (p = 0.0380). In surgical specimens both median CD105- and CD31-assessed MVD were significantly higher in TSR low/stroma-rich than in TSR high/stroma-poor patients (p = 0.0089 and p = 0.0391). In the univariate Cox's model, TSR predicted disease-free survival (DFS) in both biopsies and surgical specimens (p = 0.0003 and p = 0.0002). DFS was associated with CD105- and CD31-assessed MVD in biopsies (p < 0.0001 for both) and surgical specimens (p < 0.0001 for both). Considering biopsies, the multivariate analysis found both TSR (p = 0.0032; HR = 6.112, 95%CI: 1.833-20.378) and CD105-assessed MVD (p = 0.0002; HR = 1.201, 95%CI: 1.090-1.322) as DFS predictor. In paired surgical specimens, both TSR (p = 0.0074; HR = 6.137, 95%CI: 1.626-23.172) and CD105-assessed MVD (p = 0.0005; HR = 1.172 95 %CI 1.071-1.282) retained their significance in multivariate analysis.
CONCLUSIONS: If confirmed by large prospective studies, TSR and MVD could be proposed as prognostic biomarkers of LSCC for a possible treatment intensification or targeted therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
Oral oncology - 132(2022) vom: 01. Sept., Seite 105982 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alessandrini, Lara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, CD |
|---|
| Anmerkungen: |
Date Completed 26.07.2022 Date Revised 19.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.oraloncology.2022.105982 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342808427 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342808427 | ||
| 003 | DE-627 | ||
| 005 | 20231226014954.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2022.105982 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342808427 | ||
| 035 | |a (NLM)35759860 | ||
| 035 | |a (PII)S1368-8375(22)00271-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alessandrini, Lara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor-stroma ratio, neoangiogenesis and prognosis in laryngeal carcinoma. A pilot study on preoperative biopsies and matched surgical specimens |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.07.2022 | ||
| 500 | |a Date Revised 19.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVES: The interaction between tumor cells and stroma is critical in tumorigenesis, tumor neo-angiogenesis and cancer progression. The aims of this study were to: (i) evaluate the concordance between tumor-stroma ratio (TSR) and microvascular density (MVD) on paired biopsy and surgical specimens of laryngeal carcinoma (LSCC); (ii) investigate the association of TSR with angiogenesis (CD105- and CD31-assessed MVD); (iii) assess the prognostic role of TSR and MVD evaluated on preoperative biopsies and paired surgical specimens | ||
| 520 | |a METHODS: TSR, CD105- and CD31-assessed MVD were analyzed in paired biopsies and surgical specimens of 43 consecutive cases | ||
| 520 | |a RESULTS: TSR showed good agreement between biopsies and surgical specimens (AC1 statistic: 0.7957). In biopsies, TSR low/stroma-rich cases showed higher CD105-assessed MVD (p = 0.0380). In surgical specimens both median CD105- and CD31-assessed MVD were significantly higher in TSR low/stroma-rich than in TSR high/stroma-poor patients (p = 0.0089 and p = 0.0391). In the univariate Cox's model, TSR predicted disease-free survival (DFS) in both biopsies and surgical specimens (p = 0.0003 and p = 0.0002). DFS was associated with CD105- and CD31-assessed MVD in biopsies (p < 0.0001 for both) and surgical specimens (p < 0.0001 for both). Considering biopsies, the multivariate analysis found both TSR (p = 0.0032; HR = 6.112, 95%CI: 1.833-20.378) and CD105-assessed MVD (p = 0.0002; HR = 1.201, 95%CI: 1.090-1.322) as DFS predictor. In paired surgical specimens, both TSR (p = 0.0074; HR = 6.137, 95%CI: 1.626-23.172) and CD105-assessed MVD (p = 0.0005; HR = 1.172 95 %CI 1.071-1.282) retained their significance in multivariate analysis | ||
| 520 | |a CONCLUSIONS: If confirmed by large prospective studies, TSR and MVD could be proposed as prognostic biomarkers of LSCC for a possible treatment intensification or targeted therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biopsy | |
| 650 | 4 | |a CD105 | |
| 650 | 4 | |a CD31 | |
| 650 | 4 | |a Laryngeal carcinoma | |
| 650 | 4 | |a Microvascular density | |
| 650 | 4 | |a Tumor-stroma ratio | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Endoglin |2 NLM | |
| 650 | 7 | |a Receptors, Cell Surface |2 NLM | |
| 700 | 1 | |a Ferrari, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Taboni, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Sbaraglia, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Franz, Leonardo |e verfasserin |4 aut | |
| 700 | 1 | |a Saccardo, Tommaso |e verfasserin |4 aut | |
| 700 | 1 | |a Del Forno, Bianca Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Agugiaro, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Frigo, Anna Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Dei Tos, Angelo Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Marioni, Gino |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d 1998 |g 132(2022) vom: 01. Sept., Seite 105982 |w (DE-627)NLM091475074 |x 1879-0593 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2022 |g day:01 |g month:09 |g pages:105982 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.oraloncology.2022.105982 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2022 |b 01 |c 09 |h 105982 | ||